JP5718319B2 - Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー - Google Patents

Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー Download PDF

Info

Publication number
JP5718319B2
JP5718319B2 JP2012511029A JP2012511029A JP5718319B2 JP 5718319 B2 JP5718319 B2 JP 5718319B2 JP 2012511029 A JP2012511029 A JP 2012511029A JP 2012511029 A JP2012511029 A JP 2012511029A JP 5718319 B2 JP5718319 B2 JP 5718319B2
Authority
JP
Japan
Prior art keywords
her2
cells
activation
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012511029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526992A5 (https=
JP2012526992A (ja
Inventor
フィリップ キム
フィリップ キム
シンジュン リュウ
シンジュン リュウ
リチャード カークランド
リチャード カークランド
タニ イ
タニ イ
ベレン イバルロンド
ベレン イバルロンド
シャラット シン
シャラット シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2012526992A publication Critical patent/JP2012526992A/ja
Publication of JP2012526992A5 publication Critical patent/JP2012526992A5/ja
Application granted granted Critical
Publication of JP5718319B2 publication Critical patent/JP5718319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012511029A 2009-05-14 2010-05-13 Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー Active JP5718319B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US17845809P 2009-05-14 2009-05-14
US61/178,458 2009-05-14
US18078709P 2009-05-22 2009-05-22
US61/180,787 2009-05-22
US18724609P 2009-06-15 2009-06-15
US61/187,246 2009-06-15
US22852209P 2009-07-24 2009-07-24
US61/228,522 2009-07-24
US23564609P 2009-08-20 2009-08-20
US61/235,646 2009-08-20
US24180409P 2009-09-11 2009-09-11
US61/241,804 2009-09-11
US26285609P 2009-11-19 2009-11-19
US61/262,856 2009-11-19
US26522709P 2009-11-30 2009-11-30
US61/265,227 2009-11-30
PCT/US2010/034814 WO2010132723A1 (en) 2009-05-14 2010-05-13 Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy

Publications (3)

Publication Number Publication Date
JP2012526992A JP2012526992A (ja) 2012-11-01
JP2012526992A5 JP2012526992A5 (https=) 2013-06-27
JP5718319B2 true JP5718319B2 (ja) 2015-05-13

Family

ID=42315848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012511029A Active JP5718319B2 (ja) 2009-05-14 2010-05-13 Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー

Country Status (7)

Country Link
US (1) US9726669B2 (https=)
EP (1) EP2430443B1 (https=)
JP (1) JP5718319B2 (https=)
AU (1) AU2010248884B2 (https=)
CA (1) CA2761777A1 (https=)
NZ (2) NZ596468A (https=)
WO (1) WO2010132723A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295259A1 (en) * 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
CN102822676B (zh) 2010-01-12 2015-02-18 雀巢产品技术援助有限公司 用于预测三阴性乳腺癌对疗法的应答的方法
EP2656077A1 (en) 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
SG192270A1 (en) 2011-02-17 2013-08-30 Nestec Sa Apparatus and method for isolating leukocytes and tumor cells by filtration
WO2012119113A2 (en) 2011-03-02 2012-09-07 Nestec Sa Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP2694972B8 (en) 2011-04-04 2017-08-16 Pierian Holdings, Inc. Methods for predicting and improving the survival of gastric cancer patients
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
WO2012154935A1 (en) * 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
EP2788752B1 (en) 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
EP2605014A1 (en) * 2011-12-16 2013-06-19 Merck Patent GmbH General strategy for antibody library screening
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
JP2015532425A (ja) 2012-10-05 2015-11-09 ネステク ソシエテ アノニム 粘膜治癒を予測及びモニタリングするための方法
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20140221368A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
JP6202362B2 (ja) * 2013-03-04 2017-09-27 国立大学法人北海道大学 乳癌乳房温存療法後の局所再発リスクの予測に用いるための診断薬並びに予測方法
WO2014188363A1 (en) 2013-05-21 2014-11-27 Nestec S.A. Methods for predicting and improving the survival of colorectal cancer patients
WO2015017788A1 (en) * 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
WO2015028974A2 (en) 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
KR101527797B1 (ko) * 2014-06-03 2015-06-15 한국과학기술원 신호전달경로의 활성화 상태 분석방법 및 이를 이용한 개인 맞춤형 치료제의 선정방법
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
DK3230736T3 (da) * 2014-12-12 2020-06-08 Celcuity Inc Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
JP2015127711A (ja) * 2015-02-10 2015-07-09 公立大学法人横浜市立大学 初期乳癌の検出方法
CN104762264A (zh) * 2015-04-20 2015-07-08 安徽安科生物工程（集团）股份有限公司 曲妥珠单抗耐药的人乳腺癌细胞株及其制备方法和应用
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
WO2018175251A1 (en) 2017-03-20 2018-09-27 Celcuity Llc Methods of measuring signaling pathway activity for selection of therapeutic agents
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
WO2019126168A1 (en) * 2017-12-21 2019-06-27 Proplex Technologies, LLC Sensitive detection of g-protein coupled receptor-associated sorting protein 1 (gasp-1). gasp-1 microvesicles, and gasp-1 exosomes
WO2021108043A1 (en) 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
CN119614505B (zh) * 2023-09-12 2025-12-05 珠海圣美生物诊断技术有限公司 稀有细胞捕获试剂组合及方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7695926B2 (en) * 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP4443407B2 (ja) * 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2521077A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
WO2005117553A2 (en) * 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
US20080254497A1 (en) * 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
DK2064549T3 (da) * 2006-09-21 2013-02-04 Nestec Sa Antistof-baserede arrays til detektion af flere signaltransducere i sjældne cirkulerende celler
EP2115464A4 (en) * 2007-03-01 2012-07-25 Targeted Molecular Diagnostics Llc METHOD AND COMPOSITIONS FOR DETERMINING THE EFFECT OF BREAST CANCER THERAPEUTICS
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
US20090017050A1 (en) * 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
ES2526211T3 (es) * 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
JP2011522212A (ja) * 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
CA2711843C (en) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
NZ617520A (en) * 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP2438443A4 (en) * 2009-06-02 2012-07-25 Targeted Molecular Diagnostics Llc METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2)
US10444235B2 (en) * 2009-06-23 2019-10-15 Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
WO2011031982A1 (en) 2009-09-10 2011-03-17 Myriad Genetics, Inc. Methods and compositions for predicting cancer therapy response
PT2330131E (pt) * 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611

Also Published As

Publication number Publication date
US20110071042A1 (en) 2011-03-24
AU2010248884A1 (en) 2012-01-12
CA2761777A1 (en) 2010-11-18
EP2430443B1 (en) 2018-06-27
AU2010248884B2 (en) 2015-04-02
NZ616755A (en) 2015-05-29
EP2430443A1 (en) 2012-03-21
WO2010132723A1 (en) 2010-11-18
US9726669B2 (en) 2017-08-08
NZ596468A (en) 2013-11-29
JP2012526992A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
JP5718319B2 (ja) Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
DK2602623T3 (en) METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
CN103384828A (zh) 使用基于抗体的阵列进行恶性癌症疗法的药物选择
AU2013205274B2 (en) Drug selection for breast cancer therapy using antibody-based arrays
HK1185414B (en) Drug selection for breast cancer therapy using antibody-based arrays

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150318

R150 Certificate of patent or registration of utility model

Ref document number: 5718319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250